Cytokinetics Inc., of South San Francisco, said the enrollment of the approximately 450 patients has been completed in the planned expansion phase of the COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure) trial testing omecamtiv mecarbil.